ASCO GI 2023 | Immunotherapy combinations in pancreaticobiliary cancers

Kim Anna Reiss, MD, University of Pennsylvania, Philadelphia, PA, talks on immunotherapy combinations in pancreaticobiliary cancers, accounting for the potential for unique biology in certain patients, either relating to a DNA damage repair variant or a patient’s immunobiology. A study on the cessation of chemotherapy in exchange for a PARP inhibitor with anti-CTLA4 in patients who had achieved a durable response with chemotherapy revealed this patient population may be immunologically distinct, this bearing clinical implications. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.